Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide

被引:123
作者
Wei, ZL
Bai, O
Richardson, JS
Mousseau, DD
Li, XM
机构
[1] Univ Saskatchewan, Neuropsychiat Res Unit, Coll Med, Dept Psychiat, Saskatoon, SK S7N 5E3, Canada
[2] Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 0W0, Canada
关键词
SOD-1; neuroleptics; hydrogen peroxide; neuroprotection;
D O I
10.1002/jnr.10668
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuroanatomical studies suggest that neuronal atrophy and destruction occur over the course of many years in neurodegenerative conditions such as schizophrenia and Alzheimer's disease. In schizophrenia, early intervention with atypical neuroleptics such as olanzapine has been shown to prevent development of some of the more serious and debilitating symptoms in many patients. The mechanisms whereby olanzapine slows or prevents symptom progression in schizophrenia remain unclear. A previous study found that olanzapine increased mRNA for the copper/zinc isoform of the superoxide dismutase enzyme (SOD-1). We investigated the effects of olanzapine in PC12 cells exposed to hydrogen peroxide. We measured cell viability, observed evidence of necrosis and apoptosis, checked the SOD-1 mRNA by Northern blot analyses, and determined SOD-1 enzyme activity. We found that: 1) the decrease in cell viability induced by hydrogen peroxide was attenuated in PC12 cells pre-treated with olanzapine; 2) olanzapine increased SOD enzyme activity in PC12 cells; 3) inhibiting SOD activity with diethyldithiocarbamic acid prevented the cytoprotective actions of olanzapine; and 4) the decrease in SOD-1 mRNA level induced by hydrogen peroxide was blocked by pretreatment with olanzapine. These data indicate that the neuroprotective action of olanzapine includes the upregulation of SOD. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:364 / 368
页数:5
相关论文
共 32 条
[1]   Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease [J].
Behl, C .
CELL AND TISSUE RESEARCH, 1997, 290 (03) :471-480
[2]   A comparative review of new antipsychotics [J].
Blin, O .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1999, 44 (03) :235-244
[3]   New dimensions in the pharmacologic treatment of schizophrenia and related psychoses [J].
Buckley, PF .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (05) :363-378
[4]   OXIDATIVE STRESS, GLUTAMATE, AND NEURODEGENERATIVE DISORDERS [J].
COYLE, JT ;
PUTTFARCKEN, P .
SCIENCE, 1993, 262 (5134) :689-695
[5]   Antioxidants, oxidative stress, and degenerative neurological disorders [J].
Floyd, RA .
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 222 (03) :236-245
[6]   REACTIVE OXYGEN SPECIES AND THE CENTRAL-NERVOUS-SYSTEM [J].
HALLIWELL, B .
JOURNAL OF NEUROCHEMISTRY, 1992, 59 (05) :1609-1623
[7]   NERVE GROWTH-FACTOR EFFECTS ON PYRIDINE-NUCLEOTIDES AFTER OXIDANT INJURY OF RAT PHEOCHROMOCYTOMA CELLS [J].
JACKSON, GR ;
WERRBACHPEREZ, K ;
EZELL, EL ;
POST, JFM ;
PEREZPOLO, JR .
BRAIN RESEARCH, 1992, 592 (1-2) :239-248
[8]  
Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8
[9]   OXYGEN FREE-RADICALS AND BRAIN-DYSFUNCTION [J].
JESBERGER, JA ;
RICHARDSON, JS .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1991, 57 (1-2) :1-17
[10]   POTENTIATED NECROSIS OF CULTURED CORTICAL-NEURONS BY NEUROTROPHINS [J].
KOH, JY ;
GWAG, BJ ;
LOBNER, D ;
CHOI, DW .
SCIENCE, 1995, 268 (5210) :573-575